Investors / Spain / Namarel Ventures
Namarel Ventures
Venture capital · Barcelona, Spain · Europe
Namarel Ventures is an early-stage investor specialized in healthcare that provides funding and sector expertise to innovative companies. It invests in medical devices, diagnostics and digital health solutions, and began its investment activity in 2018.
Invests inHealthcare & Biotech
In its own wordshealthcaremedical devicesdiagnosticsdigital healthimpact
Your fit with Namarel Ventures
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsNamarel Ventures lists 15 checked portfolio companies on its own site and is named in 2 funding rounds. Its most frequent entry is Seed, 100% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 89% of its companies are based in Spain. It invests most often alongside Ship2B Ventures, Ship2B Foundation and Asabys Partners.
Counts come from funding rounds that name Namarel Ventures, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Namarel Ventures' whole history. Rounds on record name 2 companies; its own site lists 15. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 100% |
| Series A | 0% |
| Series B | 0% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 0 |
| '26 | 1 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 39th | 15 companies |
| Recent activity | 59th | 1 rounds in 12 months |
| Early stage | 100th | 100% of entries at pre-seed or seed |
| Evidence | 84th | 13% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 42th | 2 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Ship2B Ventures | 3 |
| Ship2B Foundation | 2 |
| Asabys Partners | 1 |
| Athos Capital | 1 |
| Clave | 1 |
| Conector | 1 |
| Convergence Partners | 1 |
| Criteria Bio Ventures | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers15100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare Namarel Ventures head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Namarel Ventures| Date | Company | Stage |
|---|---|---|
| 18 Mar 2026 | Round | |
| 23 Jan 2025 | Seed |
Round details for Namarel Ventures
Amounts, full round histories and every co-investor in Namarel Ventures' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
15 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Cebiotex is a Phase 2 clinical-stage biotechnology company developing innovative local therapies for oncology. | Healthcare & Biotech | Portfolio page | ||
| Corify has developed a cardiac mapping system that enables real-time beat-to-beat global cardiac mapping in under 10 minutes from patient arrival | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| Deneb Medical develops and provides a spine surgery station to assist surgeons in all phases of spine procedures | Healthcare & Biotech | Portfolio page | ||
| ELEM Biotech develops healthcare digital twins platforms for pharmaceutical companies, clinical research organizations, and regulators | Healthcare & Biotech | Portfolio page | ||
| Mar 2026Round | Page + round | |||
| Inbiomotion develops a test to help select breast cancer patients for adjuvant treatment with bisphosphonates | Healthcare & Biotech | Portfolio page | ||
| Innitius develops medical hardware and software for obstetric diagnostics and preterm birth diagnosis | Healthcare & Biotech | Portfolio page | ||
| Leuko develops a noninvasive device for white blood cell measurement | Healthcare & Biotech | Portfolio page | ||
| Magentiq develops and offers AI-aided colonoscopy technology | Healthcare & Biotech | Portfolio page | ||
| Mimark develops a diagnostic approach that uses gynecological fluids to diagnose gynecological diseases efficiently and accurately. | Healthcare & Biotech | Portfolio page | ||
| Omniscope decodes an individual's immune repertoire across time to track clonal dynamics and identify cellular drivers of chronic disease and accelerated aging. | Healthcare & Biotech | Portfolio page | ||
| Pharmacelera develops proprietary Computer-Aided Drug Design software based on accurate Quantum-Mechanics algorithms, Machine Learning and High-Performance Computing | Healthcare & Biotech | Portfolio page | ||
| Predictheon accurately predicts adverse events, yielding improved health outcomes, savings and value for all stakeholders. | Healthcare & Biotech | Portfolio page | ||
| Sycai Medical develops an AI-powered assistant that detects pre-cancerous lesions at a benign stage | Healthcare & Biotech | Jan 2025Seed | Page + round |
About this data
site last read 5 Nov 2026- Site
- namarelventures.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 23 Jan 2025
- Companies checked
- 15
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Namarel Ventures' profile as data
Pull Namarel Ventures' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/namarelventures.com
# also
GET /v1/firms/namarelventures.com/portfolio
GET /v1/firms/namarelventures.com/coinvestors
GET /v1/firms/namarelventures.com/news